Skip to main content
NVDA-2.47%AAPL+1.18%GOOGL-0.43%MSFT-0.18%AMZN-0.04%TSM-2.13%SPCX+1.74%AVGO-0.27%META-0.65%TSLA-0.38%SKHY-5.22%MU-3.82%BRK-B-0.01%LLY+0.41%JPM-0.82%AMD-2.64%WMT+0.89%V-0.32%XOM+0.15%ASMLa-3.01%JNJ0.00%INTC-5.77%MA-0.27%0700.HK-1.94%ORCL-2.65%1398.HK+0.79%BAC-0.41%ABBV+0.61%CSCO-0.30%CVX-0.69%COST+0.22%LRCX-4.40%KO+1.35%CAT-1.64%AMAT-2.69%0005.HK-0.78%AP2d-1.98%UNH+0.66%DELL-3.11%HSBA.L-1.42%MS-0.42%PG+0.02%GE-0.24%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.09%HD-1.23%GS-0.92%0939.HK+1.66%NZDJPY-2.69%AUDJPY-2.02%CHFJPY-1.71%USDJPY-1.50%GBPJPY-1.49%EURJPY-1.44%CADJPY-1.41%EURNZD+1.31%NZDCAD-1.30%NZDUSD-1.23%GBPNZD+1.21%NZDCHF-1.02%USDNOK+0.96%USDZAR+0.88%EURNOK+0.85%CHFNOK+0.80%EURZAR+0.78%NOKJPY-0.73%AUDNZD+0.70%GBPZAR+0.66%USDSEK+0.65%AUDCAD-0.64%AUDDKK-0.62%USDMXN+0.60%EURAUD+0.60%EURSEK+0.54%AUDUSD-0.53%AUDSGD-0.52%GBPAUD+0.51%CHFSEK+0.49%USDTHB+0.49%GBPTRY+0.41%USDPLN+0.34%GBPHKD+0.32%AUDCHF-0.32%NZDSGD-0.29%GBPMXN-0.28%CADCHF+0.28%EURCHF+0.26%EURPLN+0.23%AUDNOK+0.23%USDCHF+0.22%USDSGD+0.21%GBPCHF+0.20%USDILS+0.16%EURHKD-0.13%PLNJPY-0.11%USDDKK+0.11%USDTRY+0.11%GBPCAD-0.10%EURSGD+0.10%NZDMXN+0.08%EURGBP+0.08%USDCAD-0.07%EURUSD+0.06%USDCNH+0.05%CHFSGD+0.04%USDCOP-0.04%EURCNH-0.04%GBPSGD-0.03%SGDJPY+0.03%EURCAD-0.02%EURCZK0.00%USDHKD0.00%EURDKK0.00%GBPUSD0.00%XPTUSD-4.55%HG1-4.30%XAGUSD-4.25%GAGUSD-4.25%UKOIL+2.75%USOIL+2.44%COFFEE-1.86%XAUUSD-0.88%GAUUSD-0.88%W1-0.85%COCOA-0.70%C1-0.42%BTCUSD-1.50%ETHUSD-1.40%USDTUSD-0.05%XRPUSD-2.26%SOLUSD-1.91%TRXUSDT-0.06%ZECUSDT-6.27%DOGEUSD-2.82%XMRUSDT-1.63%LINKUSD-1.27%XLMUSD-1.99%BCHUSDT-9.63%LTCUSD-1.54%UNIUSD-3.92%HBARUSDT-1.68%TONUSD+24.88%SUIUSD-3.17%TAOUSDT-4.43%AAVEUSD-2.97%DOTUSDT-3.07%ICPUSDT-0.65%ONDOUSDT-2.84%WLDUSDT-2.67%ATOMUSDT-3.03%ARBUSDT+1.71%JUPUSDT-2.96%INJUSDT-3.59%STXUSDT-3.43%FETUSDT-2.98%TIAUSDT-1.13%PYTHUSDT-1.00%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-4.89%GRTUSDT-3.13%OPUSDT-3.00%IOTAUSDT-3.54%POLUSDT-6.59%AXSUSDT-2.47%FARTCOINUSDT-2.79%EOSUSDT-1.18%DYDXUSDT-0.88%ORDIUSDT-0.61%GALAUSDT-4.21%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.47%AAPL+1.18%GOOGL-0.43%MSFT-0.18%AMZN-0.04%TSM-2.13%SPCX+1.74%AVGO-0.27%META-0.65%TSLA-0.38%SKHY-5.22%MU-3.82%BRK-B-0.01%LLY+0.41%JPM-0.82%AMD-2.64%WMT+0.89%V-0.32%XOM+0.15%ASMLa-3.01%JNJ0.00%INTC-5.77%MA-0.27%0700.HK-1.94%ORCL-2.65%1398.HK+0.79%BAC-0.41%ABBV+0.61%CSCO-0.30%CVX-0.69%COST+0.22%LRCX-4.40%KO+1.35%CAT-1.64%AMAT-2.69%0005.HK-0.78%AP2d-1.98%UNH+0.66%DELL-3.11%HSBA.L-1.42%MS-0.42%PG+0.02%GE-0.24%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.09%HD-1.23%GS-0.92%0939.HK+1.66%NZDJPY-2.69%AUDJPY-2.02%CHFJPY-1.71%USDJPY-1.50%GBPJPY-1.49%EURJPY-1.44%CADJPY-1.41%EURNZD+1.31%NZDCAD-1.30%NZDUSD-1.23%GBPNZD+1.21%NZDCHF-1.02%USDNOK+0.96%USDZAR+0.88%EURNOK+0.85%CHFNOK+0.80%EURZAR+0.78%NOKJPY-0.73%AUDNZD+0.70%GBPZAR+0.66%USDSEK+0.65%AUDCAD-0.64%AUDDKK-0.62%USDMXN+0.60%EURAUD+0.60%EURSEK+0.54%AUDUSD-0.53%AUDSGD-0.52%GBPAUD+0.51%CHFSEK+0.49%USDTHB+0.49%GBPTRY+0.41%USDPLN+0.34%GBPHKD+0.32%AUDCHF-0.32%NZDSGD-0.29%GBPMXN-0.28%CADCHF+0.28%EURCHF+0.26%EURPLN+0.23%AUDNOK+0.23%USDCHF+0.22%USDSGD+0.21%GBPCHF+0.20%USDILS+0.16%EURHKD-0.13%PLNJPY-0.11%USDDKK+0.11%USDTRY+0.11%GBPCAD-0.10%EURSGD+0.10%NZDMXN+0.08%EURGBP+0.08%USDCAD-0.07%EURUSD+0.06%USDCNH+0.05%CHFSGD+0.04%USDCOP-0.04%EURCNH-0.04%GBPSGD-0.03%SGDJPY+0.03%EURCAD-0.02%EURCZK0.00%USDHKD0.00%EURDKK0.00%GBPUSD0.00%XPTUSD-4.55%HG1-4.30%XAGUSD-4.25%GAGUSD-4.25%UKOIL+2.75%USOIL+2.44%COFFEE-1.86%XAUUSD-0.88%GAUUSD-0.88%W1-0.85%COCOA-0.70%C1-0.42%BTCUSD-1.50%ETHUSD-1.40%USDTUSD-0.05%XRPUSD-2.26%SOLUSD-1.91%TRXUSDT-0.06%ZECUSDT-6.27%DOGEUSD-2.82%XMRUSDT-1.63%LINKUSD-1.27%XLMUSD-1.99%BCHUSDT-9.63%LTCUSD-1.54%UNIUSD-3.92%HBARUSDT-1.68%TONUSD+24.88%SUIUSD-3.17%TAOUSDT-4.43%AAVEUSD-2.97%DOTUSDT-3.07%ICPUSDT-0.65%ONDOUSDT-2.84%WLDUSDT-2.67%ATOMUSDT-3.03%ARBUSDT+1.71%JUPUSDT-2.96%INJUSDT-3.59%STXUSDT-3.43%FETUSDT-2.98%TIAUSDT-1.13%PYTHUSDT-1.00%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-4.89%GRTUSDT-3.13%OPUSDT-3.00%IOTAUSDT-3.54%POLUSDT-6.59%AXSUSDT-2.47%FARTCOINUSDT-2.79%EOSUSDT-1.18%DYDXUSDT-0.88%ORDIUSDT-0.61%GALAUSDT-4.21%NOTUSDT-2.97%RONINUSDT-2.64%
MT

Maze Therapeutics, Inc. (MAZE)

NASDAQ • Healthcare

$24.58
-$1.79 (-6.8%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$25.86
Previous Close$24.58
Day Range$24.39 - $26.55
Avg. Volume (3M)372.7K
Market Cap$1.3B
52 Week Range
$20$53.65
Next EarningsIn 56 daysNov 5, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$20M
Net Income (TTM)
-$133.5M
EPS (TTM)
-$2.74
ROA (TTM)
-25.13%
Current Ratio
18.31

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+11.0%Q1 2026-$0.65
-4.7%Q2 2026-$0.45
-6.0%Q3 2026-$0.76
Next

Nov 5

in 56 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -6.0%

Maze Therapeutics’ loss per share trailed consensus in the second fiscal quarter of 2026, based on preliminary results reported August 12, 2026, with EPS of -$0.76 trailing the -$0.72 estimate (difference -$0.04) as the early-stage biotech continued investing in its genetic-medicine pipeline across kidney and metabolic disease programs. The company posted GAAP net income of roughly -$44.7 million, a -32.8% year-over-year change from about -$33.7 million a year ago, alongside GAAP operating income of around -$48.0 million. Cash use also remained elevated, with negative operating cash flow of about -$15.1 million during the quarter. For the next period, consensus calls for EPS of -$0.79 on revenue of $333,333.00.

View full earnings history

About Maze Therapeutics, Inc.

Maze Therapeutics, Inc. is a NASDAQ-listed biotechnology company developing genetic-medicine candidates in the United States. In qualitative terms it is an early-stage drug developer rather than a commercial biopharma company. The pipeline centers on kidney and metabolic diseases, and the company came public in 2025.

Name
Maze Therapeutics, Inc.
CEO
Jason Coloma
Website
www.mazetx.com
Industry
Healthcare
Year Founded
2017
Employees
141

Today's Snapshot

AI-generated

MAZE closed 6.8% lower at 24.58. Maze Therapeutics presented faster progress for its experimental-drug pipeline at a Wells Fargo investor conference.

Trading Volume

Above 10d avg 395.1K

401.3K

vs S&P 500 Today

Strong Underperformance

-6.31%

Updated: September 10, 2026 at 12:07 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
MAZE displays a pronounced sell profile as the price at 24.58 sits well under most moving averages, including the 200-day level, signaling broad technical weakness while ADX shows limited trend strength. Momentum indicators reinforce the downside — MACD and CCI are negative and short-term momentum is down — even though stochastic/Williams suggest oversold readings and Bollinger positioning hints at an extreme. Volume trends via OBV are declining and ATR is elevated at about 5.69%, indicating larger intraday moves on down days. Technical takeaway: sell bias amid pervasive moving-average weakness and rising volatility.
All signals
  • EMA (5 indicators)$26.61 - $31.65
    Sell
  • RSI (14)33.12
    Neutral
  • Stochastic %K (14, 3, 3)10.98
    Buy
  • MACD Level (12, 26)-0.68
    Sell

Peers & Related Assets

SYRESpyre Therapeutics, Inc.
$86.93-4.3%
IMNMImmunome, Inc.
$26.12-2.6%
TRVITrevi Therapeutics, Inc.
$16.64-1.1%
BCRXBioCryst Pharmaceuticals, Inc.
$8.81-2.9%
ZYMEZymeworks Inc.
$27.15-3.4%
NTLAIntellia Therapeutics, Inc.
$12.21-4.2%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.